NBY RSI Chart
Last 7 days
50%
Last 30 days
50%
Last 90 days
-29.4%
Trailing 12 Months
-83.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 14.2M | 0 | 0 | 0 |
2023 | 14.3M | 15.2M | 14.6M | 14.7M |
2022 | 11.3M | 12.8M | 14.3M | 14.4M |
2021 | 9.8M | 8.0M | 8.1M | 9.8M |
2020 | 7.0M | 9.2M | 9.8M | 9.9M |
2019 | 11.1M | 10.0M | 8.5M | 6.6M |
2018 | 17.5M | 16.1M | 15.2M | 12.5M |
2017 | 13.9M | 15.3M | 16.0M | 18.2M |
2016 | 5.6M | 7.2M | 9.5M | 11.9M |
2015 | 1.4M | 2.2M | 3.3M | 4.4M |
2014 | 2.7M | 2.0M | 1.1M | 1.0M |
2013 | 6.6M | 6.5M | 4.0M | 3.5M |
2012 | 9.8M | 6.2M | 7.1M | 6.9M |
2011 | 10.2M | 12.1M | 12.8M | 11.0M |
2010 | 0 | 13.7M | 11.7M | 9.8M |
2009 | 0 | 0 | 0 | 15.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 11, 2023 | zheng yongxiang | acquired | - | - | 858 | - |
May 11, 2023 | sit swan | acquired | - | - | 858 | - |
May 11, 2023 | garlikov julie | acquired | - | - | 858 | - |
May 11, 2023 | wu mijia | acquired | - | - | 858 | - |
May 11, 2023 | freiman paul e. | acquired | - | - | 858 | - |
May 11, 2023 | zheng yenyou | acquired | - | - | 858 | - |
Dec 06, 2022 | kunin jeffrey | sold | -1.81 | 1.81 | -1.00 | president, dermadoctor, llc |
Dec 06, 2022 | kunin audrey | sold | -1.81 | 1.81 | -1.00 | chief product officer |
Nov 21, 2022 | kunin jeffrey | sold | -12,545 | 2.1049 | -5,960 | president, dermadoctor, llc |
Nov 21, 2022 | kunin audrey | sold | -12,545 | 2.1049 | -5,960 | chief product officer |
Which funds bought or sold NBY recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | unchanged | - | -15.00 | 17.00 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | -9.00 | 9.00 | -% |
May 15, 2024 | Altium Capital Management LP | sold off | -100 | -13,761 | - | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -146,629 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 34.17 | -716 | 1,597 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | added | 835 | 12,376 | 15,631 | -% |
May 15, 2024 | Hudson Bay Capital Management LP | sold off | -100 | -11,016 | - | -% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | -1.00 | 1.00 | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | - | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -7,479 | - | -% |
Unveiling NovaBay Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to NovaBay Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
NovaBay Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -29.4% | 2,631,000 | 3,727,000 | 3,265,000 | 4,610,000 | 3,124,000 | 3,643,000 | 3,826,000 | 3,662,000 | 3,273,000 | 3,586,000 | 2,265,000 | 2,133,000 | 1,807,000 | 1,888,000 | 2,170,000 | 3,984,000 | 1,892,000 | 1,704,000 | 1,615,000 | 1,789,000 | 1,491,000 |
Gross Profit | -1.2% | 1,794,000 | 1,815,000 | 1,838,000 | 2,306,000 | 1,936,000 | 1,754,500 | 2,375,000 | 1,838,000 | 1,814,000 | 1,884,500 | 1,553,000 | 1,519,000 | 1,352,000 | 1,075,000 | 1,634,000 | 1,944,000 | 1,311,000 | 1,111,000 | 1,214,000 | 1,386,000 | 1,150,000 |
Operating Expenses | -18.7% | 4,230,000 | 5,206,000 | 2,954,000 | 3,661,000 | 3,670,000 | 11,180,500 | 2,832,000 | 3,990,000 | 4,196,000 | 5,078,500 | 3,842,000 | 3,378,000 | 2,872,000 | 2,833,000 | 3,696,000 | 3,015,000 | 2,846,000 | 3,349,000 | 2,926,000 | 2,765,000 | 5,221,000 |
S&GA Expenses | -25.4% | 1,055,000 | 1,414,000 | 1,715,000 | 1,718,000 | 1,653,000 | 1,938,000 | 1,835,000 | 2,040,000 | 1,985,000 | 2,357,500 | 2,061,000 | 1,788,000 | 1,680,000 | 1,498,000 | 1,692,000 | 1,423,000 | 1,560,000 | 2,157,000 | 1,544,000 | 1,535,000 | 3,531,000 |
R&D Expenses | 375.0% | 19,000 | 4,000 | 11,000 | 27,000 | 26,000 | 65,500 | 41,000 | 40,000 | 28,000 | 8,000 | 10,000 | 21,000 | 5,000 | 36,000 | 125,000 | 115,000 | 9,000 | 18,000 | 49,000 | 32,000 | 85,000 |
EBITDA Margin | -0.9% | -0.63 | -0.63 | -0.92 | -0.79 | -0.85 | -0.73 | -0.17 | -0.36 | -0.38 | -0.59 | -0.91 | -1.04 | -1.11 | -1.10 | - | - | - | - | - | - | - |
Interest Expenses | 72.3% | 236,000 | 137,000 | 180,000 | 4,000 | 5,000 | 5,000 | 5,000 | 3,000 | 4,000 | - | - | - | - | -12,000 | 6,000 | 20,000 | 35,000 | - | - | - | - |
Income Taxes | - | - | - | - | - | - | 24,000 | - | - | - | 21.00 | - | - | - | 4,000 | - | 1,000 | - | 3,000 | - | 2,000 | 1,000 |
Earnings Before Taxes | 100.0% | - | -4,108,000 | -1,757,000 | -2,036,000 | -1,739,000 | -8,206,000 | -136,000 | -2,155,000 | -111,000 | -158,000 | -2,289,000 | -1,859,000 | -1,518,000 | -1,750,000 | -3,221,000 | -4,481,000 | -1,582,000 | -2,683,000 | -282,000 | -2,499,000 | -4,188,000 |
EBT Margin | -3.5% | -0.68 | -0.65 | -0.94 | -0.80 | -0.86 | -0.74 | -0.18 | -0.37 | -0.39 | -0.59 | -0.92 | -1.04 | -1.11 | -1.11 | - | - | - | - | - | - | - |
Net Income | 21.8% | -3,214,000 | -4,108,000 | -1,757,000 | -2,036,000 | -1,739,000 | -8,206,000 | -136,000 | -2,155,000 | -111,000 | -158,000 | -2,289,000 | -1,859,000 | -1,518,000 | -1,754,000 | -3,221,000 | -4,482,000 | -1,582,000 | -2,686,000 | -282,000 | -2,501,000 | -4,189,000 |
Net Income Margin | -19.3% | -0.78 | -0.65 | -0.94 | -0.80 | -0.86 | -0.74 | -0.18 | -0.37 | -0.39 | -0.59 | -0.92 | -1.04 | -1.11 | -1.11 | - | - | - | - | - | - | - |
Free Cashflow | -398.1% | -1,574,000 | -316,000 | -365,000 | -1,845,000 | -1,624,000 | -1,209,000 | -1,769,000 | -1,707,000 | -2,081,000 | -4,326,000 | -1,485,000 | -1,989,000 | -1,444,000 | -1,466,000 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -40.7% | 5,357 | 9,034 | 12,852 | 16,008 | 14,825 | 16,399 | 22,376 | 21,544 | 24,794 | 23,978 | 12,239 | 13,603 | 14,072 | 15,238 | 17,082 | 13,272 | 9,475 | 11,220 | 14,603 | 9,870 | 9,720 |
Current Assets | -49.8% | 3,591 | 7,154 | 8,214 | 11,216 | 9,894 | 11,332 | 10,613 | 9,459 | 12,478 | 13,170 | 11,497 | 12,772 | 13,146 | 14,242 | 16,012 | 11,908 | 7,874 | 9,381 | 12,498 | 7,496 | 7,115 |
Cash Equivalents | -41.8% | 1,823 | 3,130 | 3,472 | 4,414 | 3,746 | 5,362 | 3,868 | 3,931 | 5,641 | 7,504 | 9,028 | 10,294 | 10,508 | 11,952 | 13,413 | 8,775 | 5,708 | 6,937 | 9,020 | 3,668 | 2,932 |
Inventory | -77.0% | 663 | 2,877 | 3,493 | 3,660 | 3,797 | 3,437 | 4,068 | 3,801 | 3,437 | 3,220 | 969 | 682 | 850 | 608 | 785 | 626 | 552 | 492 | 838 | 664 | 302 |
Net PPE | -11.5% | 77.00 | 87.00 | 97.00 | 108 | 119 | 119 | 217 | 166 | 187 | 193 | 96.00 | 94.00 | 100 | 84.00 | 76.00 | 84.00 | 97.00 | 110 | 128 | 177 | 193 |
Goodwill | - | - | - | 348 | 348 | 348 | 348 | 4,528 | 4,500 | 4,500 | 4,528 | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | -9.1% | 5,197 | 5,720 | 5,815 | 7,445 | 5,935 | 5,845 | 8,592 | 5,799 | 7,048 | 13,807 | 2,875 | 2,394 | 3,089 | 2,920 | 3,200 | 12,289 | 9,824 | 10,247 | 11,096 | 8,201 | 8,591 |
Current Liabilities | -8.3% | 3,924 | 4,278 | 4,571 | 6,066 | 4,423 | 4,257 | 3,710 | 3,657 | 4,784 | 3,442 | 2,874 | 2,389 | 3,080 | 2,833 | 3,003 | 4,301 | 5,483 | 5,687 | 6,252 | 3,352 | 5,414 |
LT Debt, Current | -14.4% | 973 | 1,137 | 1,270 | 1,185 | - | - | - | - | - | - | - | - | - | - | - | 418 | 954 | 1,409 | 1,890 | - | - |
Shareholder's Equity | -95.2% | 160 | 3,314 | 7,037 | 8,563 | 8,890 | 10,554 | 13,784 | 15,745 | 17,746 | 10,171 | 9,364 | 11,209 | 10,983 | 12,318 | 13,882 | 983 | - | 973 | 2,923 | 1,669 | 1,129 |
Retained Earnings | -2.1% | -178,443 | -174,849 | -165,680 | -163,923 | -159,891 | -158,152 | -149,946 | -144,153 | -141,998 | -141,887 | -141,729 | -139,440 | -137,581 | -136,063 | -134,309 | -131,088 | -126,606 | -125,024 | -122,338 | -122,056 | -119,526 |
Additional Paid-In Capital | 0.4% | 176,798 | 176,101 | 170,675 | 169,689 | 165,156 | 165,713 | 162,510 | 158,793 | 158,621 | 150,900 | 150,643 | 150,202 | 148,146 | 147,963 | 147,774 | 131,725 | 125,975 | 125,718 | 125,009 | 123,518 | 120,484 |
Shares Outstanding | 168.0% | 30,098 | 11,230 | 6,529 | 4,214 | 2,035 | 2,035 | 1,514 | 1,507 | 1,431 | 1,365 | 1,231 | 1,205 | 1,194 | 1,194 | - | - | - | - | - | - | - |
Float | - | - | - | - | 3,050 | - | - | - | 10,875 | - | - | - | 23,677 | - | - | - | 26,683 | - | - | - | 15,628 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -400.6% | -1,572 | -314 | -363 | -1,843 | -1,611 | -1,209 | -1,689 | -1,699 | -2,057 | -4,318 | -1,468 | -1,987 | -1,419 | -1,445 | -1,370 | -1,041 | -865 | -1,429 | -1,500 | -1,779 | -3,221 |
Cashflow From Investing | 53500.0% | 1,068 | -2.00 | -2.00 | -2.00 | -13.00 | - | -80.00 | -8.00 | -24.00 | -12,001 | -17.00 | -2.00 | -25.00 | -21.00 | -5.00 | - | - | - | - | -5.00 | -14.00 |
Cashflow From Financing | -2196.2% | -597 | -26.00 | -577 | 2,513 | - | 3,035 | 1,703 | - | -105 | 14,795 | 219 | 1,775 | - | 5.00 | 6,013 | 4,108 | -364 | -654 | 6,852 | 2,520 | 2,984 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Sales: | ||
Total sales, net | $ 2,631 | $ 2,339 |
Cost of goods sold | 837 | 739 |
Gross profit | 1,794 | 1,600 |
Operating expenses | ||
Research and development | 19 | 10 |
Sales and marketing | 1,055 | 1,236 |
General and administrative | 2,291 | 1,699 |
Loss on divestiture of subsidiary | 865 | 0 |
Total operating expenses | 4,230 | 2,945 |
Operating loss | (2,436) | (1,345) |
Non-cash gain on changes in fair value of warrant liabilities | 194 | 0 |
Non-cash gain on change in fair value of embedded derivative liability | 65 | 0 |
Accretion of interest and amortization of discounts on convertible notes | (433) | 0 |
Other expense, net | (480) | 0 |
Net loss from continuing operations | (3,090) | (1,345) |
Net loss from discontinued operations (Note 17) | (124) | (394) |
Net loss | (3,214) | (1,739) |
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price | 380 | 0 |
Net loss attributable to common stockholders | $ (3,594) | $ (1,739) |
Basic and diluted net loss per share | ||
Net loss per share from continuing operations (in dollars per share) | $ (0.14) | $ (0.66) |
Net loss per share from discontinued operations (in dollars per share) | (0.01) | (0.19) |
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share) | $ (0.15) | $ (0.85) |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares) | 24,672 | 2,035 |
Product [Member] | ||
Sales: | ||
Total sales, net | $ 2,624 | $ 2,332 |
Product and Service, Other [Member] | ||
Sales: | ||
Total sales, net | $ 7 | $ 7 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
ASSETS | ||
Cash and cash equivalents | $ 1,823 | $ 2,924 |
Accounts receivable, net of allowance for credit losses ($3 at March 31, 2024 and December 31, 2023) | 734 | 680 |
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($229 and $264 at March 31, 2024 and December 31, 2023, respectively) | 663 | 564 |
Prepaid expenses and other current assets | 371 | 256 |
Current assets, discontinued operations | 0 | 2,730 |
Total current assets | 3,591 | 7,154 |
Operating lease right-of-use assets | 1,212 | 1,296 |
Property and equipment, net | 77 | 87 |
Other assets | 477 | 478 |
Other assets, discontinued operations | 0 | 19 |
TOTAL ASSETS | 5,357 | 9,034 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Accounts payable | 1,117 | 906 |
Accrued liabilities | 1,266 | 1,169 |
Secured Convertible Notes, net of discounts | 973 | 1,137 |
Unsecured Convertible Notes, net of discounts | 34 | 0 |
Embedded derivative liability | 159 | 0 |
Operating lease liability | 375 | 368 |
Current liabilities, discontinued operations | 0 | 698 |
Total current liabilities | 3,924 | 4,278 |
Warrant liabilities | 232 | 334 |
Operating lease liabilities-non-current | 1,041 | 1,108 |
Total liabilities | 5,197 | 5,720 |
Commitments and contingencies (Note 8) | ||
Stockholders’ equity: | ||
Common stock, $0.01 par value; 150,000 shares authorized, 32,025 and 11,230 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 320 | 112 |
Additional paid-in capital | 176,798 | 176,101 |
Accumulated deficit | (178,443) | (174,849) |
Total stockholders’ equity | 160 | 3,314 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 5,357 | 9,034 |
Series B Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred Stock | 44 | 275 |
Series C Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred Stock | $ 1,441 | $ 1,675 |